| Literature DB >> 34183040 |
J van der Veen1, A Gulyban2, S Willems3, F Maes3, S Nuyts4.
Abstract
BACKGROUND: In radiotherapy inaccuracy in organ at risk (OAR) delineation can impact treatment plan optimisation and treatment plan evaluation. Brouwer et al. showed significant interobserver variability (IOV) in OAR delineation in head and neck cancer (HNC) and published international consensus guidelines (ICG) for OAR delineation in 2015. The aim of our study was to evaluate IOV in the presence of these guidelines.Entities:
Keywords: Contouring; Guidelines; Head and neck; Interobserver variability; Organs at risk
Mesh:
Year: 2021 PMID: 34183040 PMCID: PMC8240214 DOI: 10.1186/s13014-020-01677-2
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Median and range of DSC, MSD and HD95 per OAR
| DSC | MSD (mm) | HD95 (mm) | Nr. of contours by RO using Brouwer et al. guidelines (max = 27) | Nr. of contours by RO using no/other guidelines (max = 35) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | Range | Median | Range | Median | Range | ||||||
| Min | Max | Min | Max | Min | Max | ||||||
| Brainstem | 0.88 | 0.61 | 0.92 | 1.5 | 1.1 | 4.0 | 4.0 | 2.3 | 15.0 | 24 (89%) | 31 (89%) |
| Cochlea left | 0.45 | 0.00 | 0.79 | 1.9 | 0.8 | 11.0 | 3.7 | 1.9 | 14.9 | 16 (59%) | 9 (26%) |
| Cochlea right | 0.38 | 0.00 | 0.83 | 2.1 | 0.9 | 10.5 | 4.1 | 1.5 | 14.4 | 16 (59%) | 9 (26%) |
| Glottic area | 0.45 | 0.17 | 0.87 | 2.8 | 0.9 | 8.4 | 9.4 | 1.8 | 18.5 | 13 (48%) | 10 (29%) |
| Mandible | 0.90 | 0.79 | 0.94 | 1.1 | 0.8 | 8.3 | 3.4 | 1.5 | 38.7 | 26 (96%) | 29 (83%) |
| Oral cavity | 0.77 | 0.45 | 0.91 | 4.6 | 1.8 | 11.6 | 14.5 | 4.3 | 30.1 | 19 (70%) | 23 (66%) |
| Parotid left | 0.82 | 0.62 | 0.88 | 1.9 | 1.2 | 4.2 | 4.9 | 3.1 | 16.5 | 27 (100%) | 35 (100%) |
| Parotid right | 0.83 | 0.51 | 0.90 | 2.0 | 1.4 | 4.9 | 5.1 | 3.2 | 19.2 | 26 (96%) | 35 (100%) |
| PCM-inferior | 0.53 | 0.00 | 0.78 | 2.9 | 1.1 | 16.8 | 12.2 | 2.6 | 78.0 | 12 (44%) | 6 (17%) |
| Middle | 0.53 | 0.29 | 0.82 | 3.8 | 0.9 | 13.4 | 12.1 | 2.0 | 36.0 | 12 (44%) | 7 (20%) |
| Superior | 0.50 | 0.19 | 0.73 | 2.6 | 1.3 | 6.7 | 10.5 | 3.2 | 27.5 | 12 (44%) | 7 (20%) |
| Spinal cord | 0.78 | 0.56 | 0.90 | 2.2 | 0.8 | 10.4 | 12.1 | 1.7 | 72.1 | 17 (63%) | 34 (97%) |
| SMG left | 0.87 | 0.57 | 0.91 | 1.3 | 0.9 | 3.4 | 3.1 | 1.8 | 12.2 | 26 (96%) | 24 (69%) |
| SMG right | 0.87 | 0.72 | 0.92 | 1.2 | 0.9 | 2.5 | 3.1 | 1.9 | 10.1 | 27 (100%) | 24 (69%) |
| Supragl. larynx | 0.65 | 0.11 | 0.86 | 3.5 | 1.0 | 13.3 | 9.6 | 3.0 | 28.7 | 11 (41%) | 9 (26%) |
Median and range were calculated over all delineations made by all radiation oncologists on all cases. The number of delineations varies for each OAR as shown in the 2 right columns. Radiation oncologists who use the guidelines from Brouwer et al. delineate the cochleas, glottic area, PCSM,s, SMG and supraglottic larynx more than other radiation oncologists. The spinal cord however was delineated less, because 2 RO delineated the spinal canal instead
DSC Dice Similarity Coefficient, HD95 95% Hausdorff distance, mm millimetre, MSD mean surface distance, PCM pharyngeal constrictor muscles, RO radiation oncologist, SMG submandibular gland, Supragl supraglottic
Fig. 1Overall mean surface distance. The boxplot shows better agreement with the reference contour when the ICG from Brouwer et al. are used by the RO compared to other RO (p = 0.008). mm millimetre, ICG international consensus guidelines, MSD mean surface distance, RO radiation oncologists
Fig. 2Mean surface distances for the different OARs. This figure shows better agreement with the reference contour when the guidelines from Brouwer et al. are used (yellow). Diamond shape markers represent outliers (more than 1.5 × interquartile range above the upper quartile and below the lower quartile). mm millimetre, MSD mean surface distance, PCM pharyngeal constrictor muscle, SMG submandibular gland
Short description of delineation guidelines per organ at risk, the errors delineated and possible consequences
| Organ at risk | International consensus guidelines [ | Errors | Consequences of errors |
|---|---|---|---|
| Brainstem | Cranial: bottom section of the lateral ventricles Caudal: tip of the dens of C2 | Cranial: start when the brainstem becomes visible (all RO) Caudal: different interpretation of “tip” so a few slices difference | No impact on relevant dose parameter for precise NTCP (Dmax), depending on tumour location. But can effect estimated dose to spinal cord which has a more strict dose constraint |
| Cochlea | CT scan in bone setting, cochlea in temporal bone | Incorrect location (2 RO) Entire petrous part of the temporal bone delineated (3 RO) | Effect on dose when wrong location is delineated Difference in volume can have an impact on Dmean and Dmax depending on tumour location |
| Glottic area | Cranial: cranial tip of arytenoids Caudal: caudal edge of thyroid cartilage Posterior: cricoid, anterior border of arytenoids Enclosed by the thyroid cartilage | Entire larynx delineated, starting caudal of the hyoid and including the thyroid cartilage and arytenoids (2 RO) Included caudal part of supraglottic larynx (2 RO) Included arytenoids (2 RO) | Impact on relevant dose parameter for precise NTCP (Dmean) |
| Mandible | CT scan in bone setting Excluding teeth, including mandibular condyles and coronoid process | Teeth included (not systematically, but some RO in some cases) Mandibular condyles and coronoid process not included (1 RO systematically) | No impact on relevant dose parameter for precise NTCP (Dmax), depending on tumour location |
| Oral cavity | Cranial: Hard palate mucosa and mucosal reflections near the maxilla Caudal: base of tongue mucosa and hyoid posteriorly and the mylohyoid and anterior belly of the digastric muscle anteriorly Anterior and lateral: inner side of the mandible and maxilla Posterior: soft palate, uvula and base of tongue | Included teeth (two RO) Included the buccal mucosa (1 RO) Excluded posterior part of oral cavity (1 RO) Excluded base of tongue (1 RO) | Impact on relevant dose parameter for precise NTCP (Dmean) |
| Parotid gland | Cranial: external auditory canal, mastoid process Caudal: posterior part submandibular space Anterior: Masseter muscle, posterior border mandibular bone, pterygoid muscle (med. and lat.) Posterior: sternocleidomastoid muscle, lateral side posterior belly digastric muscle Lateral: platysma and subcutaneous fat Medial: Posterior belly of the digastric muscle, styloid process, para-pharyngeal space | Cranial and caudal borders varied up to a few slices between RO Anterior: sometimes inclusion of the masseter and pterygoid muscles Medial: digastric muscle sometimes included | Impact on relevant dose parameter for precise NTCP (Dmean) |
| PCM inferior [ | Caudal: lower edge of arytenoids Cranial: first slice caudal to the hyoid bone | Caudal: several slices difference between RO | Impact on relevant dose parameter for precise NTCP (Dmean) |
| PCM middle [ | Cranial: cranial border of C3 Caudal: caudal border of hyoid bone | Cranial: cranial border stopped at caudal border of C3 (3 RO). Only 2 RO delineated cranially enough | Impact on relevant dose parameter for precise NTCP (Dmean) |
| PCM superior [ | Cranial: tips of the pterygoid plates (hamulus) Caudal: caudal border of C2 | Cranial: 1 RO delineated the superior muscle up to the base of skull | Impact on relevant dose parameter for precise NTCP (Dmean) |
| Spinal cord | Spinal cord, not canal Cranial: tip of dens of C2 Caudal: At least cranial edge of T3, lower for more caudal tumours | Spinal canal delineated (2 RO) Cranial: some difference depending on what was interpreted as “tip” of dens of C2 Caudal: not caudal enough, stopped several slices too high (3 RO, each in one patient) | No impact on relevant dose parameter for precise NTCP (Dmax), depending on tumour location. But can effect estimated dose to brainstem which has a less strict dose constraint |
| Submandibular gland | Cranial: medial pterygoid muscle and mylohyoid muscle Caudal: fatty tissue Anterior: lateral surface mylohyoid muscle and hyoglossus muscle Posterior: para-pharyngeal space, sternocleidomastoid muscle Lateral: medial surface medial pterygoid muscle, mandible, platysma Medial: lateral surface mylohyoid muscle, hyoglossus muscle, superior and middle PCM, anterior belly digastric muscle | Cranial: some variation in cranial border between RO | Impact on relevant dose parameter for precise NTCP (Dmean) |
| Supraglottic larynx | Cranial: tip of epiglottis Caudal: cranial edge of arytenoids Posterior: inferior PCM, pharyngeal lumen Confined by the thyroid cartilage and hyoid bone, exclude pharyngeal lumen | Cranial: entire pharyngeal lumen delineated at the tip of the epiglottis (1 RO) Caudal: delineation 2–3 cm more caudal than guidelines (2 RO) | Impact on relevant dose parameter for precise NTCP (Dmean) |
For detailed description of contour guidelines, see Brouwer et al. [18] and Christianen et al. [21]
NTCP normal tissue complication probability, Dmean mean dose, Dmax maximum dose, PCM pharyngeal constrictor muscle, RO radiation oncologist
Fig. 3CT images showing different OAR contours Reference contours according to the ICG (lilac) vs delineations from the different RO. a brainstem (sagittal plane): difference in cranial and caudal borders; b oral cavity, spinal cord and PG (axial plane): Inclusion of buccal mucosa (green contour) and teeth (orange and pink contours) by some RO. Variation in spinal cord and PG contours; c spinal cord (sagittal plane): difference in cranial and caudal borders. ICG international consensus guidelines, PG parotid glands, RO radiation oncologist